Payment overview · 2025
General Payments
$465.01
24 reported records · 10 companies
Healthcare provider profile · identity verified
Hunter Harrison, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WEST MONROE, LA · NPI 1205218393
Verified facts
What the public records show
CMS Open Payments records show Hunter Harrison, D.O. received $465.01 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.76 | 23.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.48 | 17.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.58 | 14.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.58 | 10.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.43 | 8.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.45 | 6.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.87 | 6.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.72 | 5.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.46 | 4.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.68 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.01 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $90.82 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $90.82 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $90.82 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.48 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $72.30 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.87 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 132 |
| Gabapentin | Gabapentin | 330 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 99 |
| Lisinopril | Lisinopril | 262 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 72 |
| Losartan Potassium | Losartan Potassium | 196 | 64 |
| Omeprazole | Omeprazole | 192 | 54 |
| Meloxicam | Meloxicam | 182 | 50 |
| Metformin Hcl | Metformin Hcl | 165 | 54 |
| Naproxen | Naproxen | 157 | 60 |
| Trazodone Hcl | Trazodone Hcl | 157 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 48 |
| Furosemide | Furosemide | 141 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 46 |
| Mounjaro | Tirzepatide | 116 | 22 |
| Baclofen | Baclofen | 109 | 33 |
| Clonazepam | Clonazepam | 107 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 34 |
| Prednisone | Prednisone | 99 | 68 |
| Ipratropium Bromide | Ipratropium Bromide | 93 | 70 |
| Simvastatin | Simvastatin | 92 | 30 |
| Eliquis | Apixaban | 84 | 23 |
| Sertraline Hcl | Sertraline Hcl | 84 | 30 |
| Potassium Chloride | Potassium Chloride | 83 | 24 |
| Carvedilol | Carvedilol | 80 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 27 |
| Alprazolam | Alprazolam | 69 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 19 |
| Glimepiride | Glimepiride | 68 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 19 |
| Methocarbamol | Methocarbamol | 55 | 17 |
| Azithromycin | Azithromycin | 54 | 51 |
| Allopurinol | Allopurinol | 53 | 19 |
| Jardiance | Empagliflozin | 53 | 17 |
| Montelukast Sodium | Montelukast Sodium | 49 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 17 |
| Pregabalin | Pregabalin | 48 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Clonidine Hcl | Clonidine Hcl | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Finasteride | Finasteride | 42 | 15 |
| Buspirone Hcl | Buspirone Hcl | 40 | 12 |
| Cefdinir | Cefdinir | 40 | 33 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Nifedipine Er | Nifedipine | 39 | 15 |
| Nystatin | Nystatin | 39 | 17 |
| Lorazepam | Lorazepam | 38 | 11 |
| Atenolol | Atenolol | 37 | suppressed |
| Linzess | Linaclotide | 37 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 12 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Famotidine | Famotidine | 30 | 13 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 15 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 17 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | 20 |
| Estradiol | Estradiol | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Topiramate | Topiramate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 11 |
| Latanoprost | Latanoprost | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $465.01 · 24 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, VOQUEZNA, Veozah, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error